摘要
Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy by restoring the host antitumor immune response. Since 2011, various ICIs have been approved for the treatment of cancers, which has led to unprecedented prolongation of the survival time for some patients. Although ICIs have been successfully applied in the treatment of different cancers, the low effectiveness rate has dramati-cally restrained the clinical application of ICI treatment. N6-methyladenosine (m6A) modification is the most common RNA methylation. Recent studies have pointed out that m6A epigenetic modification could improve the efficacy of ICI blockade treatment. Here, we briefly summarize the relevant mecha-nisms of tumour immunity, the clinical application of ICIs, the resistance to ICI treatment in cancers, and the m6A epigenetic modification and how it regulates the response to ICI treatment. We attempted to provide a potential strategy for cancer therapy by targeting m6A modification combined with ICI blockade treatment. CO 2022 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creative-commons.org/licenses/by-nc-nd/4.0/).
学科与关键词
- Targeting RNA N6-methyladenosine modification: a precise weapon in overcoming tumor immune escapeLi, Wei; Hao, Yi; Zhang, Xingda; Xu, Shouping*; Pang, Da*Molecular Cancer, 2022, 21(1): 176.被引 12
- N6-methyladenosine RNA Methylation Correlates with Immune Microenvironment and Immunotherapy Response of MelanomaWang, Gaofeng; Zeng, Dongqiang; Sweren, Evan; Miao, Yong; Chen, Ruosi; Chen, Junjun; Wang, Jin; Liao, Wangjun; Hu, Zhiqi; Kang, Sewon; Garza, Luis A.*Journal of Investigative Dermatology, 2023, 143(8).被引 1
- N6-methyladenosine RNA modifications: a potential therapeutic target for AMLHu, Rong; Liao, Peiyun; Xu, Binyan; Qiu, Yingqi; Zhang, Honghao; Li, Yuhua*Annals of Hematology, 2023.
